drugset / Trial / NCT06685978

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

NCT06685978 ↗

Phase 3 Recruiting 430 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).

Timeline

Start
2024-04-26
Primary completion
2026-04-30
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Xiang Ju Ru Pi Ning capsule Traditional medicine (herbal / TCM) 0.45 g Oral

Indications